CA-GLOBALLOGIC
8.4.2024 14:38:30 CEST | Business Wire | Press release
GlobalLogic, a Hitachi group company, today announced a first-of-its-kind Platform-of-Platforms architecture designed to support deployment of enterprise-grade artificial intelligence (AI). GlobalLogic has designed the architecture to address the critical challenges every enterprise must overcome when operationalizing AI and generative AI (GenAI) at scale.
To realize the potential that AI promises, enterprises must address data privacy and security requirements, prevent intellectual property (IP) leakage and manage legal risks. They also need to identify an approach that allows for technical agility as new models, platforms and other innovations take shape. At the same time, leaders must manage organizational change and find effective strategies for controlling costs and driving return on AI/GenAI investments.
With over a decade of experience in delivering and deploying AI in software products and enterprise platforms, GlobalLogic offers a unique perspective on the design, data and engineering challenges of enterprise-grade, production-ready AI and GenAI. Created in partnership with leading hyperscalers and leveraging their foundational GenAI capabilities, GlobalLogic’s architecture is the first of its kind for unifying and industrializing enterprise-grade AI and GenAI solutions.
GlobalLogic identifies responsibility, reliability and reusability as key to enterprise-grade AI
“As companies work to move from AI and GenAI prototypes to enterprise-scale deployments, it has become clear that using this technology requires far more than sending prompts to a large language model (LLM),” said Sumit Sood, COO and Head of Engineering, GlobalLogic. “We have been helping enterprises adopt GenAI since 2021 and ‘traditional’ AI for much longer, often in life-critical situations. We understand what needs to be done to ensure responsibility, reliability and reusability in AI platforms.”
Sood explains that the responsibility tenet focuses on the goal of offering responses that are accurate, lawful and in compliance with security and governance requirements. The reliability tenet requires mechanisms for correcting model drift, hallucinations and security threats over time. Finally, the reusability tenet is crucial to implementing common data ingestion, preparation and model training and shared consumption mechanisms – which help contain costs and mitigate risk by preventing duplicative work.
GlobalLogic’s AI Platform-of-Platforms architecture addresses critical needs related to observability, security, governance and consumption. It makes it possible to integrate best-of-breed models, algorithms and solutions whether deployed in the cloud or on premises. It also includes accelerators for rapidly deploying some of the most sought-after use cases, including customer support and operations, software development and legacy migration, and enterprise knowledge management.
“The GenAI landscape is highly dynamic,” Sood said. “In an environment where the ‘best’ technology can change month to month or even week to week, GlobalLogic’s Platform-of-Platforms approach lets our clients pick the winners to deliver the best enterprise-class GenAI to support their business outcomes.”
To learn more about GlobalLogic’s AI solutions and advisory capabilities, visit www.globallogic.com/services/offerings/generative-ai/.
ABOUT GLOBALLOGIC
GlobalLogic (www.globallogic.com) is a leader in digital engineering. We help brands across the globe design and build innovative products, platforms, and digital experiences for the modern world. By integrating experience design, complex engineering, and data expertise—we help our clients imagine what’s possible and accelerate their transition into tomorrow’s digital businesses. Headquartered in Silicon Valley, GlobalLogic operates design studios and engineering centers around the world, extending our deep expertise to customers in the automotive, communications, financial services, healthcare and life sciences, manufacturing, media and entertainment, semiconductor, and technology industries. GlobalLogic is a Hitachi Group Company operating under Hitachi, Ltd. (TSE: 6501), which contributes to a sustainable society with a higher quality of life by driving innovation through data and technology as the Social Innovation Business.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240408417447/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OpenRouter Raises $113 Million CapitalG-led Series B as Weekly Volume Explodes to 25T Tokens26.5.2026 15:15:00 CEST | Press release
NVentures, ServiceNow Ventures, MongoDB Ventures, Snowflake Ventures, Databricks Ventures join CapitalG, a16z, Menlo Ventures, and others in backing the high-growth AI infrastructure startup OpenRouter, the AI model exchange, today announced a $113 million Series B led by Alphabet’s independent growth fund, CapitalG, with participation from investors including NVentures (NVIDIA’s venture capital arm), ServiceNow Ventures, MongoDB Ventures, Snowflake Ventures, Databricks Ventures, alongside existing investors including Andreessen Horowitz and Menlo Ventures. OpenRouter’s volume has surged to 25 trillion tokens per week (100 trillion tokens per month), representing a 5X increase from the 5 trillion tokens processed per week just six months ago. The explosion in token demand illustrates how quickly enterprises are deploying agents and scaling AI across multiple models and providers. OpenRouter’s infrastructure manages and optimizes inference and provides access to 400+ models across leadi
Xsolla Expands Its Community Management Tools for Creators, Community Leaders, and Resellers26.5.2026 15:00:00 CEST | Press release
Xsolla Adds New Features For Creators, Community Leader Experience, And Distinct Channels For Emerging Markets Xsolla, a leading global video game commerce company, today announced three simultaneous expansions of its community management tools and products. As the creator economy continues to reshape how games are discovered and the industry accelerates its shift toward direct-to-consumer commerce, Xsolla is building on its community management tools for creators, community leaders, and emerging markets, and will showcase them at TwitchCon Rotterdam later this month. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260526596720/en/ Graphic: Xsolla The games industry has never had a shortage of people who drive player acquisition, loyalty, and commerce; it's had a shortage of infrastructure that recognizes them. Creators stream it. Community leaders build a culture around it. Local resellers get it into the hands of players in
Biocytogen Launches AI-Powered RenSuper™ Platform and Industry-First Fully Automated Antibody Discovery Infrastructure26.5.2026 14:00:00 CEST | Press release
Biocytogen today announced the launch of RenSuper Workstation, a next-generation AI-powered antibody discovery platform providing off-the-shelf access to a large-scale, experimentally validated library of fully human therapeutic antibody sequences, together with the RenSuper High-Throughput Antibody Manufacturing Automation Center, a fully automated infrastructure designed to accelerate antibody validation and production. Built on Biocytogen’s proprietary RenMice® platforms, RenSuper establishes a closed-loop antibody discovery engine combining in vivo immune repertoires, AI-driven candidate selection, automated experimental validation, and scalable manufacturing infrastructure. The platform supports the discovery and development of monoclonal antibodies, bispecifics, multispecifics, antibody-drug conjugates (ADCs), VHHs, and other advanced therapeutic modalities, significantly reducing the time and risk associated with antibody discovery. RenSuper Workstation: AI-Powered One-Click Tar
ViaLase Announces Global Commercial Introduction of the FLIGHT Procedure26.5.2026 14:00:00 CEST | Press release
First commercial femtosecond laser image-guided, high precision trabeculotomy (FLIGHT) treatments mark a new era in interventional glaucoma; one where precision, safety, and the patient experience define the new standard of care ViaLase, Inc., a commercial stage medical technology company pioneering incision-free, laser-based solutions for glaucoma, today announced the successful completion of the first commercial FLIGHT procedures performed at Centre for Sight in London by Sheraz Daya, MD, and Gus Gazzard, MD, and at Breyer, Kaymak & Klabe Augenchirurgie in Düsseldorf, Germany, by Karsten Klabe, MD. The first commercial FLIGHT procedures were performed using the ViaLuxe® Laser System to deliver an incision-free, image-guided femtosecond laser treatment designed to create precise channels through the trabecular meshwork to restore aqueous outflow and reduce intraocular pressure in patients with open-angle glaucoma. “Centre for Sight has always been committed to bringing meaningful inno
BioIVT to Spotlight ADME-Tox Expertise and Solutions at Summer 2026 Events26.5.2026 14:00:00 CEST | Press release
Company will demonstrate how high-quality, well-characterized biospecimens are critical to the success of both new approach methodologies (NAMs) and traditional studies BioIVT, the leading biospecimen solutions provider and global research partner for drug and diagnostic development, today announced it will showcase its broad portfolio of ADME-Tox solutions and research expertise at several leading industry events, including the 2026 MPS World Summit and the ISSX 16th European Meeting. The MPS World Summit takes place May 26-May 29, 2026, in Washington, D.C. BioIVT colleagues will be available at booth #115 to discuss research questions and needs, including preparation, handling, and utilization of the high-quality tissues and cells needed for microphysiological systems (MPS), as well as conducting ADME studies and bioanalysis. BioIVT offers an extensive range of control and disease state biospecimens, including SPHEROID CERTIFIED™ Hepatocytes as well as advanced HEPATOPAC® co-cultures
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
